Loading
Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer.
Mansoor Raza Mirza was principal investigator of NOVA, the first trial showing PARP inhibitor maintenance (niraparib) benefits recurrent ovarian cancer regardless of BRCA status, and of RUBY, which showed dostarlimab plus chemotherapy improves survival in primary advanced or recurrent endometrial cancer, most dramatically in mismatch repair-deficient disease. He chairs ENGOT and leads the Nordic Society of Gynaecological Oncology trial unit.
Shares Endometrial cancer, Ovarian cancer and the tags endometrial, trialist.
Shares PARP, PARP inhibitors, Ovarian cancer and the tags ovarian, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Ovarian cancer and the tags ovarian, trialist.
Shares Niraparib, Dostarlimab, PARP inhibitors, Ovarian cancer.
Shares Niraparib, PARP, PARP inhibitors and the tag trialist.
Shares PARP, PARP inhibitors, Ovarian cancer and the tag ovarian.